Skip to content

US · NTRA · MEDICAL - DIAGNOSTICS & RESEARCH

Natera, Inc. (NTRA) intrinsic value and stock valuation

$273.40as of 2026-11-21 · Mkt cap 39.33B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Natera, Inc. DCF and intrinsic value

InvestorsCraft values NTRA with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from NTRA’s statements →

Natera, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Austin, TX 78753 natera.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$2.31B+42.6% 5y CAGRd
20122025
Net income
-$-208.16M
20122025
Free cash flow
$109.1M
20122025
Total equity
$1.71B+28.6% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$2.31B$1.7B$1.08B$820.2M$625.5M
Operating income-$-309.91M-$-222.29M-$-446.25M-$-541.04M-$-468.17M
Net income-$-208.16M-$-190.43M-$-434.8M-$-547.8M-$-471.72M
EPSd-$-1.52M-$-1.53M-$-3.78M-$-5.57M-$-5.21M
Operating cash flow$215.3M$135.7M-$-246.96M-$-431.5M-$-335.24M
Capital expenditure-$-106.19M-$-66.42M-$-39.2M-$-47.7M-$-41.03M
Free cash flow$109.1M$69.2M-$-286.15M-$-479.2M-$-376.27M
Total assets$2.51B$1.66B$1.44B$1.39B$1.24B
Total debt$214.4M$187.1M$442M$446.2M$397.2M
Net debt-$-861.76M-$-758.47M-$-200.1M-$-19.87M$312.9M
Total equity$1.71B$1.2B$765.3M$705.7M$653.3M
Cash and short-term investments$1.08B$968.3M$879M$898.4M$914.3M
Income statement
20252024202320222021
Revenue$2.31B$1.7B$1.08B$820.2M$625.5M
Cost of revenue$810.6M$673.8M$589.8M$456.3M$318.4M
Gross profit$1.5B$1.02B$492.7M$364M$307.1M
Research and development expenses$624.1M$404.1M$320.7M$316.4M$264.2M
Selling, general and administrative expenses$1.18B$841.3M$618.3M$588.6M$511M
Other expenses$4.03M$0.00$0.00$0.00$0.00
Operating expenses$1.81B$1.25B$939M$905M$775.2M
Cost and expenses$2.62B$1.92B$1.53B$1.36B$1.09B
Interest income$45.9M$43.3M$24.4M$3.54M$5.38M
Interest expense$4.07M$10.7M$12.6M$9.32M$8.3M
Depreciation and amortization$43.5M$31M$38.6M$30.5M$11.3M
Ebitda-$-220.54M-$-148.08M-$-383.28M-$-507.03M-$-451.54M
Operating income-$-309.91M-$-222.29M-$-446.25M-$-541.04M-$-468.17M
Total other income/expenses, net$41.8M$32.6M$11.7M-$-5.78M-$-2.92M
Income before tax-$-268.09M-$-189.73M-$-434.53M-$-546.82M-$-471.1M
Income tax expense-$-59.93M$690K$270K$980K$620K
Net income-$-208.16M-$-190.43M-$-434.8M-$-547.8M-$-471.72M
Weighted average shares outstanding$136.7M$124.7M$115M$98.4M$90.6M
Weighted average diluted shares outstanding$136.7M$124.7M$115M$98.4M$90.6M
Balance sheet
20252024202320222021
Cash and short-term investments$1.08B$968.3M$879M$898.4M$914.3M
Net receivables$296.5M$314.2M$278.3M$244.4M$122.1M
Inventory$68.4M$44.7M$40.8M$35.4M$26.9M
Total current assets$1.5B$1.38B$1.26B$1.21B$1.09B
Property, plant and equipment, net$349.7M$248.2M$167.8M$164.3M$124.5M
Goodwill and intangible assets$514.8M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.01B$284.9M$183.2M$182.7M$143.4M
Total assets$2.51B$1.66B$1.44B$1.39B$1.24B
Accounts payable$33.2M$34.9M$15M$31.2M$27.2M
Short-term debt$95.9M$90.5M$92M$88M$55.8M
Deferred revenue$24.9M$19.8M$16.6M$10.8M$7.4M
Total current liabilities$441.2M$344.1M$307.3M$310.5M$219M
Long-term debt$118.5M$96.6M$350M$358.2M$341.4M
Deferred revenue, non-current$17.1M$16.8M$19.1M$20M$21.3M
Total non-current liabilities$354.4M$121.3M$369.1M$378.2M$364.2M
Capital lease obligations$134.1M$106.8M$78.7M$84.2M$66.8M
Total liabilities$795.6M$465.3M$676.4M$688.7M$583.2M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-2.78B-$-2.57B-$-2.38B-$-1.94B-$-1.39B
Accumulated other comprehensive income (loss)-$-260K-$-340K-$-3.08M-$-16.36M-$-2.29M
Total equity$1.71B$1.2B$765.3M$705.7M$653.3M
Total investments$0.00$22.7M$236.9M$432.3M$829.9M
Total debt$214.4M$187.1M$442M$446.2M$397.2M
Net debt-$-861.76M-$-758.47M-$-200.1M-$-19.87M$312.9M
Cash flow statement
20252024202320222021
Net income-$-208.16M-$-190.43M-$-434.8M-$-547.8M-$-471.72M
Depreciation and amortization$43.5M$31M$24.1M$16.7M$11.3M
Stock-based compensation$354.4M$274.4M$191.8M$152.4M$115.2M
Change in working capital$10M$2.14M-$-47.95M-$-83.15M-$-45.6M
Accounts receivable$20.8M-$-35.88M-$-33.9M-$-122.31M-$-43.51M
Inventory-$-20.87M-$-3.98M-$-5.35M-$-8.5M-$-6.88M
Accounts payable$750K$13.2M-$-15.46M$5.46M$19.2M
Net cash provided by operating activities$215.3M$135.7M-$-246.96M-$-431.5M-$-335.24M
Investments in property, plant and equipment-$-139.19M-$-66.42M-$-39.2M-$-47.7M-$-41.03M
Acquisitions, net-$-16.02M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-132.21M$137.6M$168.5M$330.3M-$-205.19M
Common stock issued$47.5M$30.3M$254.5M$452.6M$576.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$47.5M$30.2M$254.5M$482.6M$576.2M
Net change in cash$130.6M$303.5M$176M$381.5M$35.8M
Cash at end of period$1.08B$945.6M$642.1M$466.1M$84.6M
Operating cash flow$215.3M$135.7M-$-246.96M-$-431.5M-$-335.24M
Capital expenditure-$-106.19M-$-66.42M-$-39.2M-$-47.7M-$-41.03M
Free cash flow$109.1M$69.2M-$-286.15M-$-479.2M-$-376.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Natera, Inc.

        Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

        CEO
        Steven Leonard Chapman
        Employees
        6.14K
        Beta
        1.50

        Explore

        Frequently asked questions

        What is the intrinsic value of Natera, Inc. (NTRA)?

        Natera, Inc. (NTRA) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NTRA undervalued?

        NTRA trades at a price of $273.40 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.